Skip to main content
    RT @Janetbirdope: What happens to #Sjogrens tests over time? Well nothing- serology and tests are stable over time for

    Janet Pope Janetbirdope

    1 year 4 months ago
    What happens to #Sjogrens tests over time? Well nothing- serology and tests are stable over time for NIH in >2800 Pts from 1984-2020 in well characterized Pts. Abst#2025 #ACR22 @RheumNow I was surprised as I thought there would be worsening but if prevalent Pts already fibrotic?
    RT @RichardPAConway: Wheeler et al. MUC5B assoc risk RA-ILD, OR 2.25. No significant additive interaction with race, smo

    Richard Conway RichardPAConway

    1 year 4 months ago
    Wheeler et al. MUC5B assoc risk RA-ILD, OR 2.25. No significant additive interaction with race, smoking, disease activity @RheumNow #ACR22 Abstr#2250 https://t.co/Hw2oBawKsd https://t.co/DqCQIPpEyg
    RT @AkhilSoodMD: Abstr #2195 COVID PrEP in Rheum pts who did not seroconvert after 3rd dose
    - anti-SARS-CoV2 IgG levels

    Akhil Sood MD AkhilSoodMD

    1 year 4 months ago
    Abstr #2195 COVID PrEP in Rheum pts who did not seroconvert after 3rd dose - anti-SARS-CoV2 IgG levels ↑ after day 1 - Saliva IgG also ↑ up to day 14 - one reported COVID+ w mild symptoms @RheumNow #ACR22 https://t.co/um2JFNMhpj
    RT @RichardPAConway: Zuo @RayZuoMD @jasonsknight et al. High levels of anti-NET antibodies in 45% of aPL-positive patien

    Richard Conway RichardPAConway

    1 year 4 months ago
    Zuo @RayZuoMD @jasonsknight et al. High levels of anti-NET antibodies in 45% of aPL-positive patients May activate the complement cascade and contribute to brain white matter changes. @RheumNow #ACR22 Abstr#2269 https://t.co/JrjNvQRDim https://t.co/c4yXHLOmBJ
    RT @Janetbirdope: ILD in #scleroderma. #Scleroderma lung study III - NO DIFF between MMF + Pirfenidone vs MMF alone. Pla

    Janet Pope Janetbirdope

    1 year 4 months ago
    ILD in #scleroderma. #Scleroderma lung study III - NO DIFF between MMF + Pirfenidone vs MMF alone. Planned for 150 Pts but only 51 enrolled but p=0.9. A trial recruited during #COVID so difficult to enroll Abst#530 @RheumNow #ACR22 https://t.co/CBYEJ2YCVM
    RT @DrCassySims: How does #COVID19 impact pregnant women with rheumatic disease? Does vaccination status make a differen

    Catherine Sims, MD DrCassySims

    1 year 4 months ago
    How does #COVID19 impact pregnant women with rheumatic disease? Does vaccination status make a difference? @RheumNow #ACR22 https://t.co/2oJ1RAeciN https://t.co/c9s6QRSOR4
    RT @Janetbirdope: #Vasculitis #ACR22 highlights. #Rituximab more remission in clinical care for GPA - observational, les

    Janet Pope Janetbirdope

    1 year 4 months ago
    #Vasculitis #ACR22 highlights. #Rituximab more remission in clinical care for GPA - observational, less infections if 600 mg IV fixed q6 mo how long to continue? Abst#1084 and less flares w Rituximab maintenance in the MAINRITSAN studies abst#527 Ritux is new SoC in GPA @RheumNow
    RT @RichardPAConway: Aggarwal @docrota et al. ProDERM results on skin and QoL. Statistically significant improvements in

    Richard Conway RichardPAConway

    1 year 4 months ago
    Aggarwal @docrota et al. ProDERM results on skin and QoL. Statistically significant improvements in CDASI (both activity and damage) and SF-36. @RheumNow #ACR22 Abstr#2239 https://t.co/vsnvYUla13
    RT @RHEUMarampa: Let's review how GCs induce #Osteoporosis 👇(every Rheum should know this!)
    💊GCs have bone cell sp

    sheila RHEUMarampa

    1 year 4 months ago
    Let's review how GCs induce #Osteoporosis 👇(every Rheum should know this!) 💊GCs have bone cell specific effects on: 💠Osteoclasts ⬆️resorption, survival 💠Osteoblasts ⬇️🦴formation & prolif; ⬆️apoptosis 💠Osteocytes ⬆️apoptosis & skeletal fragility #ACR22 @RheumNow @rheumarhyme https://t.co/n61OXkmRgr
    RT @RichardPAConway: Espinosa-Ortega et al. Effect of DM ab on damage (as per MDI) over time. Most damage in PM/Scl>s

    Richard Conway RichardPAConway

    1 year 4 months ago
    Espinosa-Ortega et al. Effect of DM ab on damage (as per MDI) over time. Most damage in PM/Scl>seronegative>other abs @RheumNow #ACR22 Abstr#2241 https://t.co/g8xTRyw6NZ https://t.co/sR1tT2QmU3
    RT @uptoTate: BKZ resulted in clinically meaningful improvements in FACIT-Fatigue and pain (PtAAP) in approximately half

    Dr. Rachel Tate uptoTate

    1 year 4 months ago
    BKZ resulted in clinically meaningful improvements in FACIT-Fatigue and pain (PtAAP) in approximately half of pts w/ active PsA who are bDMARD-naïve or TNFi-IR. Abs 2119 #ACR22 @RheumNow https://t.co/29gzmMZRlG https://t.co/qziqGNxQih
    RT @uptoTate: After 1st TNFi, cycling/swapping strategies both acceptable in PsA w/ similar retention rates. Further stu

    Dr. Rachel Tate uptoTate

    1 year 4 months ago
    After 1st TNFi, cycling/swapping strategies both acceptable in PsA w/ similar retention rates. Further studies needed to perform survival subgroup analysis regarding different extra-articular manifestations and PsA subtypes. Abs 2149 #ACR22 @RheumNow https://t.co/SRPhSiGeUI https://t.co/EYDULe52A3